Boundless Bio
BOLDBoundless Bio is a clinical-stage biotechnology company focused on developing transformative medicines for patients with oncogene-amplified cancers, a population with poor prognosis and limited treatment options. The company leverages its foundational discoveries in extrachromosomal DNA (ecDNA) biology to create a new vertical of cancer therapeutics, ecDNA-directed therapies (ecDTx), which aim to exploit unique vulnerabilities in cancer cells. With a leadership team of experienced precision oncology experts and a robust pipeline, Boundless Bio is positioned as the leader in the emerging field of ecDNA-targeted oncology. The company is unbound by convention in its mission to address a significant unmet medical need in oncology.
BOLD · Stock Price
Historical price data
AI Company Overview
Boundless Bio is a clinical-stage biotechnology company focused on developing transformative medicines for patients with oncogene-amplified cancers, a population with poor prognosis and limited treatment options. The company leverages its foundational discoveries in extrachromosomal DNA (ecDNA) biology to create a new vertical of cancer therapeutics, ecDNA-directed therapies (ecDTx), which aim to exploit unique vulnerabilities in cancer cells. With a leadership team of experienced precision oncology experts and a robust pipeline, Boundless Bio is positioned as the leader in the emerging field of ecDNA-targeted oncology. The company is unbound by convention in its mission to address a significant unmet medical need in oncology.
Technology Platform
A proprietary platform focused on targeting extrachromosomal DNA (ecDNA), a circular form of DNA that drives high-level oncogene amplification and tumor evolution in many aggressive cancers, to develop ecDNA-directed therapies (ecDTx).
Pipeline
3| Drug | Indication | Stage | Watch |
|---|---|---|---|
| BBI-355 + Erlotinib + Futibatinib + BBI-825 | Triple Negative Breast Cancer (TNBC) | Phase 1 | |
| BBI-825 | Solid Tumor | Phase 1 | |
| BBI-940 + Fulvestrant | Breast Cancer | Phase 1 |
Funding History
4Opportunities
Risk Factors
Competitive Landscape
Boundless Bio is a first-mover with no direct competitors focused on ecDNA. Its primary competition is from existing, often ineffective, targeted therapies and chemotherapies. Its differentiation lies in its foundational science, proprietary platform, and focused pipeline aimed at a root cause of cancer aggressiveness and resistance.
Competitors
Company Timeline
Founded in San Diego, United States
Series A: $105.0M
Series B: $100.0M
IPO — $185.0M